Agennix raises $13M for late-stage cancer trial

Agennix has raised $13 million in a private placement with existing shareholders. This is the first step of a plan to refinance the company. "The funds we have raised will enable us to continue full-scale enrollment in the Phase III FORTIS-M trial in non-small cell lung cancer and to prepare for meetings with regulatory authorities to discuss the next steps following the positive Phase II trial of talactoferrin in severe sepsis," said CFO said Torsten Hombeck, Ph.D. Agennix release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.